+

WO2002030353A2 - INHIBITEURS DU NF-λB - Google Patents

INHIBITEURS DU NF-λB Download PDF

Info

Publication number
WO2002030353A2
WO2002030353A2 PCT/US2001/031866 US0131866W WO0230353A2 WO 2002030353 A2 WO2002030353 A2 WO 2002030353A2 US 0131866 W US0131866 W US 0131866W WO 0230353 A2 WO0230353 A2 WO 0230353A2
Authority
WO
WIPO (PCT)
Prior art keywords
carboxylic acid
acid amide
thiophene
phenyl
acetylamino
Prior art date
Application number
PCT/US2001/031866
Other languages
English (en)
Other versions
WO2002030353A3 (fr
Inventor
James F. Callahan
Amy K. Roshak
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Priority to JP2002533800A priority Critical patent/JP2004523476A/ja
Priority to US10/398,847 priority patent/US20040024047A1/en
Priority to AU2002211663A priority patent/AU2002211663A1/en
Priority to EP01979731A priority patent/EP1324759A4/fr
Publication of WO2002030353A2 publication Critical patent/WO2002030353A2/fr
Publication of WO2002030353A3 publication Critical patent/WO2002030353A3/fr
Priority to US11/237,232 priority patent/US20060030596A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • This invention relates in general to a method of inhibiting pathological activation of the transcription factor NF- ⁇ B (nuclear factor- ⁇ B) using aminothiophene compounds. Such methods are particularly useful for treating diseases in which activation of NF- ⁇ B is implicated. More specifically, these methods may be used for inhibiting IKK- ⁇ (I ⁇ B kinase- ⁇ ) phosphorylation of I ⁇ B (inhibitory protein ⁇ B)-which prevents subsequent degradation and activation of NF- KB dimers.
  • Such methods are useful in the treatment of a variety of diseases associated with NF- ⁇ B activation including inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease) osteoarthritis; osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultraviolet radiation (UN)-induced skin damage; autoimmune diseases including systemic lupus eythematosus, multiple sclerosis, psoriatic arthritis, alkylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, cancer, including Hodgkins disease, cachexia, inflammation associated with infection and certain viral infections, including acquired immune deficiency syndrome (AIDS), adult respiratory distress syndrome, Ataxia Telangiestasia.
  • AIDS acquired immune deficiency syndrome
  • AIDS acquired immune deficiency syndrome
  • Nuclear factor KB belongs to a family of closely related dimeric transcription factor complexes composed of various combinations of the Rel/NF- ⁇ B family of polypeptides.
  • the family consists of five individual gene products in mammals, RelA (p65), NF- ⁇ Bl (p50/ pl05), NF- ⁇ B2 (p49/ pl00), c-Rel, and RelB, all of which can form hetero- or homodimers.
  • These proteins share a highly homologous 300 amino acid "Rel homology domain" which contains the DNA binding and dimerization domains.
  • Rel homology domain At the extreme C-terminus of the Rel homology domain is a nuclear translocation sequence important in the transport of NF- ⁇ B from the cytoplasm to the nucleus.
  • p65 and cRel possess potent transactivation domains at their C-terminal ends.
  • NF- ⁇ B The activity of NF- ⁇ B is regulated by its interaction with a member of the inhibitor I ⁇ B family of proteins. This interaction effectively blocks the nuclear localization sequence on the NF- ⁇ B proteins, thus preventing migration of the dimer to the nucleus.
  • a wide variety of stimuli activate NF- ⁇ B through what are likely to be multiple signal transduction pathways. Included are bacterial products (LPS), some viruses (HIV-1, HTLN-1), inflammatory cytokines (T ⁇ F , IL-1), environmental and oxidative stress and D ⁇ A damaging agents. Apparently common to all stimuli however, is the phosphorylation and subsequent degradation of I ⁇ B.
  • I ⁇ B is phosphorylated on two ⁇ -terminal serines by the recently identified I ⁇ B kinases (IKK- and IKK- ⁇ ).
  • IKK- and IKK- ⁇ sites-directed mutagenesis studies indicate that these phosphorylations are critical for the subsequent activation of ⁇ F- ⁇ B in that once phosphorylated the protein is flagged for degradation via the ubiquitin-proteasome pathway.
  • Free from MB, the active NF- ⁇ B complexes are able to translocate to the nucleus where they bind in a selective manner to preferred gene-specific enhancer sequences.
  • NF- ⁇ B cytokines and chemokines
  • cell adhesion molecules include a number of cytokines and chemokines, cell adhesion molecules, acute phase proteins, immunoregualtory proteins, eicosanoid metabolizing enzymes and anti-apoptotic genes.
  • NF- ⁇ B plays a key role in the regulated expression of a large number of pro-inflammatory mediators including cytokines such as TNF, IL- l ⁇ , IL-6 and IL-8, cell adhesion molecules, such as ICAM and NCAM, and inducible nitric oxide synthase (i ⁇ OS).
  • cytokines such as TNF, IL- l ⁇ , IL-6 and IL-8
  • cell adhesion molecules such as ICAM and NCAM
  • i ⁇ OS inducible nitric oxide synthase
  • mediators are known to play a role in the recruitment of leukocytes at sites of inflammation and in the case of i ⁇ OS, may lead to organ destruction
  • NF- ⁇ B airway inflammation
  • NF- ⁇ B has been shown to be activated. This activation may underlie the increased cytokine production and leukocyte infiltration characteristic of these disorders.
  • inhaled steroids are known to reduce airway hyperresponsiveness and suppress the inflammatory response in asthmatic airways.
  • glucocorticoid inhibition of NF- ⁇ B one may speculate that these effects are mediated through an inhibition of NF- ⁇ B.
  • Further evidence for a role of NF- ⁇ B in infl-immatory disorders comes from studies of rheumatoid synovium.
  • NF- ⁇ B is normally present as an inactive cytoplasmic complex
  • recent immunohistochemical studies have indicated that NF- KB is present in the nuclei, and hence active, in the cells comprising rheumatoid synovium.
  • NF- ⁇ B has been shown to be activated in human synovial cells in response to stimulation with TNF- ⁇ or IL-l ⁇ . Such a distribution may be the underlying mechanism for the increased cytokine and eicosanoid production characteristic of this tissue. See Roshak, A. K., et al., I. Biol. Chem., 271, 31496- 31501 (1996).
  • IKK- ⁇ has been shown in synoviocytes of rheumatoid arthritis patients and gene transfer studies have demonstrated the central role of IKK- ⁇ in stimulated inflammatory mediator production in these cells . See Aupperele et al. I. Immunology 1999. 163:427-433 and Aupperle et al. I. Immunology 2001;166:2705-11. More recently, the intra-articular administration of a wild type IKK- ⁇ adenoviral construct was shown to cause paw swelling while intra- articular administration of dominant-negative IKK- ⁇ inhibited adjuvant-induced arthritis in rat. See Tak et al. Arthritis and Rheumatism 2001 ; 44: 1897-1907.
  • NF- ⁇ B/Rel and I ⁇ B proteins are also likely to play a key role in neoplastic transformation and metastasis.
  • Family members are associated with cell transformation in vitro and in vivo as a result of overexpression, gene amplification , gene rearrangements or translocations.
  • rearrangement and/or amplification of the genes encoding these proteins are seen in 20-25% of certain human lymphoid tumors.
  • NF- ⁇ B is activated by oncogenic ras, the most common defect in human tumors and blockade of NF- ⁇ B activation inhibits ras mediated cell transformation.
  • NF- ⁇ B NF- ⁇ B
  • TNF ionizing radiation and DNA damaging agents
  • NF- ⁇ B NF- ⁇ B
  • inhibition of NF- ⁇ B has been shown to enhance apoptotic-killing by these agents in several tumor cell types.
  • inhibitors of NF-kB activation may be useful chemotherapeutic agents as either single agents or adjunct therapy.
  • NF-TCB is an inhibitor of skeletal cell differentiation as well as a regulator of cytokine-induced muscle wasting (Guttridge et al. Science; 2000; 289: 2363-2365.) further supporting the potential of NF-kB inhibitors as novel cancer therapies.
  • NF- ⁇ B inhibitors are described in C. Wahl, et al. /. Clin. Invest.
  • the marine natural product hymenialdisine is known to inhibit NF-KB. Roshak, A., et al., JPET, 283, 955-961 (1997). Breton, J. J and Chabot-FTetcher, M. C, IPET, 282, 459-466 (1997).
  • the present invention involves novel compounds and methods of using them for inhibiting the activation transcription factor NF- ⁇ B.
  • An object of the present invention is to provide a method for treating diseases which may be therapeutically modified by altering the activity of transcription factor NF- ⁇ B.
  • this invention provides a pharmaceutical composition comprising a compound according to Formula I.
  • this invention provides a method of treating diseases in which the disease pathology may be therapeutically modified by inhibiting phosphorylation and subsequent degradation of I ⁇ B by IKK- ⁇ .
  • this invention provides a method of treating diseases in which the disease pathology may be therapeutically modified by inhibiting pathological activation of NF- ⁇ B.
  • this invention provides methods for treating a variety of diseases associated with NF- ⁇ B activation including inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease) osteoarthritis, osteoporosis and fibrotic diseases, dermatosis, including psoriasis, atopic dermatitis and ultraviolet radiation (UV)-induced skin damage; autoimmune diseases including systemic lupus eythematosus, multiple sclerosis, psoriatic arthritis, alkylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, cancer, including Hodgkins disease, cachexia, inflammation associated with infection and certain viral infections, including acquired immune deficiency syndrome (AIDS), adult respiratory distress syndrome and Ataxia Telangiestasia
  • AIDS acquired immune deficiency syndrome
  • AIDS acquired immune deficiency syndrome
  • Rl is NR5R6
  • R 2 is CONH 2 , or SO 2 NH 2 ;
  • R3 is H, or halogen
  • R4 is aryl, or heteroaryl
  • R5 is H, or alkyl
  • Rg is selected from the group consisting of H, CO-Ci_6alkyl, SO2-C1-.
  • R7 is H or alkyl; provided that when R 2 is CONH 2 and R5 is H, R7 is not H;
  • Rg is aryl, or heteroaryl
  • R9 is H, or alkyl; and pharmaceutically acceptable salts, hydrates and solvates thereof.
  • Preferred compounds of the present invention are those wherein: R3 is H; R5 is H; and R ⁇ is selected from the group consisting of CO-Ci_6alkyl, SO -C ⁇ _6alkyl, CONH-R7, and SO 2 NH-Rc>;
  • More preferred compounds are those wherein Rg is CONH-R7, or SO2NH-R9.
  • the present invention also involves compounds wherein: Ri is NR5R6; R 2 is SO 2 NH 2 ; R3 is H, or halogen; R4 is aryl, or heteroaryl; R5 is H, or alkyl;
  • Rg is selected from the group consisting of H, CO-Ci_6alkyl, SO 2 -Ci_ ⁇ alkyl, CONH-R7, CONH-R 8 , CSNH-R7, CSNH-R 8 , SO 2 NH-R 8 , and SO 2 NH-R 9 ;
  • R7 is H, or alkyl;
  • R is aryl, or heteroaryl;
  • R9 is H, or alkyl.
  • Ri is NR5R6;
  • R 2 is CONH 2 ;
  • R3 is H, or halogen;
  • R4 is aryl, or heteroaryl;
  • R5 is H, or alkyl;
  • R6 is SO 2 -C ⁇ _6alkyl, SO 2 NH-R 8 , or SO NH-R 9 ;
  • R 8 is aryl, or heteroaryl; and
  • R9 is H, or alkyl.
  • Yet another embodiment of the present invention is a compound wherein: Ri is NR5R6; R 2 is CONH 2 ; R3 is H, or halogen; R4 is selected from the group consisting of aryl, and heteroaryl (except 4- pyridyl); R5 is alkyl;
  • R ⁇ is selected from the group consisting of H, CO-Ci- ⁇ alkyl, SO 2 -Ci-.
  • R7 is H, or alkyl; R is aryl, or heteroaryl;
  • R9 is H, or alkyl.
  • Compounds useful in this embodiment include:
  • Rl is NR5R6
  • R 2 is CONH 2 ;
  • R3 is H, or halogen;
  • R4 is selected from aryl (except unsubstituted phenyl),and heteroaryl (except
  • R5 is H
  • Rg is selected from the group consisting of CONH-R7, CONH-R 8 ,
  • CSNH-R7, and CSNH-R 8 , R7 is H (except when R5 is H), or alkyl;
  • R is aryl, or heteroaryl.
  • Compounds useful in this embodiment include 2-(3-Isopropyl-ureido)-5-phenyl-thiophene-3-carboxylic acid amide; 5-(3-Chloro- phenyl)-2-(3-methyl-ureido)-thiophene-3-carboxylic acid amide; 5-(4-Fluoro-phenyl)-2-(3-methyl-ureido)-thiophene-3-carboxylic acid amide; 2-(3-Ethyl-thioureido)-5-(4-fluoro-phenyl)-thiophene-3-carboxylic acid amide; 5-(4-Fluoro-phenyl)-2-(3-propyl-thioureido)-thiophene-3-carboxylic acid amide; 2-(3-Methyl-ureido)-5-phenyl-thiophene-3-carboxylic acid amide; 2-(3-Eth
  • Rl is NR5R6
  • R 2 is CONH 2 ;
  • R3 is H, or halogen
  • R4 is aryl (except unsubstituted phenyl, phenyl substituted by 1 or 2 halogens or methyl, trifluoromethyl, methoxy), or heteroaryl (except 4- pyridyl);
  • R5 is H
  • R6 is CO-Ci_6alkyl
  • the present invention further provides a preferred method of treatment of diseases associated with NF- ⁇ B activation, comprising administering to a subject in need thereof one or more compounds selected from the group consisting of
  • More preferred compounds useful in the present invention are selected from the group consisting of:
  • This invention provides methods for treating a variety of diseases associated with NF- ⁇ B activation including inflammatory and tissue repair disorders; particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease) osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultraviolet radiation (UV)- induced skin damage; autoimmune diseases including systemic lupus eythematosus, multiple sclerosis, psoriatic arthritis, alkylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, cancer, including Hodgkins disease, cachexia, inflammation associated with infection and certain viral infections, including aquired immune deficiency syndrome (AIDS), adult respiratory distress syndrome, and Ataxia Telangiestasia.
  • inflammatory and tissue repair disorders particularly rheumatoid arthritis,
  • the present invention includes all hydrates, solvates, complexes and prodrugs of the compounds of this invention.
  • Prodrugs are any covalently bonded compounds, which release the active parent, drug according to Formulas I and II in vivo. If a chiral center or another form of an isomeric center is present in a compound of the present invention, all forms of such isomer or isomers, including enantiomers and diastereomers, are intended to be covered herein.
  • Inventive compounds containing a chiral center may be used as a racemic mixture, an enantiomerically enriched mixture, or the racemic mixture may be separated using well-known techniques and an individual enantiomer may be used alone.
  • alkyl refers to an optionally substituted hydrocarbon group joined by single carbon-carbon bonds and having 1-6 carbon atoms joined together.
  • the alkyl hydrocarbon, group may be linear, branched, or cyclic, saturated or unsaturated.
  • Substituents on optionally substituted alkyl are selected from the group consisting of aryl, OH, O-alkyl, CO, halogen, CF3, and OCF3.
  • aryl refers to an optionally substituted aromatic group with at least one ring having a conjugated pi-electron system, containing up to two conjugated or fused ring systems.
  • Aryl includes carbocyclic aryl, and biaryl groups, all of which may be optionally substituted. Substituents are selected from the group consisting of halogen, C ⁇ _4 alkyl, NH 2 , OCF3 ; CF3 ; O-alkyl, S-alkyl, CN, CHO, SO 2 -alkyl and NO 2 .
  • heteroaryl refers to an optionally substituted aromatic group with at least one ring having a conjugated pi-electron system, containing up to two conjugated or fused ring systems and 1-3 heteroatoms selected from O, S and N.
  • Heteroaryl includes carbocyclic heteroarylaryl, aryl-heteroaryl and biheteroarylaryl groups, all of which may be optionally substituted.
  • Preferred aryl include phenyl and naphthyl. More preferred aryl include phenyl.
  • Preferred substituents are selected from the group consisting of halogen, Cj_4 alkyl, NH 2 , OCF3 CF3 ; O-alkyl, S- alkyl, CN, CHO, SO 2 -alkyl and NO 2 .
  • heteroaryl rings included pyrrole, furan, thiophene, indole, isoindole, benzofuran, isobenzofuran, benzothiphene, pyridine, quinoline, isoquinoline, quinolizine, pyrazole, imidazole, isoxazole, oxazole, isothiazole, thiazole, pyridazine, pyrimidine, and pyrazine.
  • halogen refers to include F, Cl, Br, and I.
  • the compounds of the present invention may be conveniently prepared by the methods set forth in Schemes 1-8 below.
  • a general solution preparation of aminothiophene carboxamides is disclosed in U.S. Patent No. 3,963,750, to A C. Goudie, incorporated herein by reference, and is described below and in Scheme 1.
  • An alternative method is described below and in Scheme 2.
  • Methods for the general preparation for the corresponding sulfonamides are outlined in Schemes 3-4.
  • a method for the general preparation of the thiophenecarboxamide urea or thiourea analogs is described in.
  • Scheme 5 and methods for.the general preparation of the thiophenesulfonamide urea or thiourea analogs is described in Scheme 6.
  • Acid addition salts of the compounds of Formula I are prepared in a standard manner in a suitable solvent from the parent compound and an excess of an acid, such as hydrochloric, hydrobromic, hydrofluoric, sulfuric, phosphoric, acetic, trifluoroacetic, maleic, succinic or methanesulfonic. Certain of the compounds form inner salts or zwitterions, which may be acceptable.
  • Cationic salts are prepared by treating the parent compound with an excess of an alkaline reagent, such as a hydroxide, carbonate or alkoxide, containing the appropriate cation; or with an appropriate organic amine.
  • Cations such as Li + , ⁇ a + , K + , Ca ++ , Mg ++ and NH4 " are specific examples of cations present in pharmaceutically acceptable salts.
  • Halides, sulfate, phosphate, alkanoates (such as acetate and trifluoroacetate), benzoates, and sulfonates (such as mesylate) are examples of anions present in pharmaceutically acceptable salts.
  • compositions of the compounds of Formula I may be used in the manufacture of a medicament.
  • Pharmaceutical compositions of the compounds of Formula I prepared as hereinbefore described may be formulated as solutions or lyophilized powders for parenteral administration. Powders may be reconstituted by addition of a suitable diluent or other pharmaceutically acceptable carrier prior to use.
  • the liquid formulation may be a buffered, isotonic, aqueous solution. Examples of suitable diluents are normal isotonic saline solution, standard 5% dextrose in water or buffered sodium or ammonium acetate solution.
  • Such formulation is especially suitable for parenteral administration, but may also be used for oral administration or contained in a metered dose inhaler or nebulizer for insufflation. It may be desirable to add excipients such as polyvinylpyrrolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.
  • excipients such as polyvinylpyrrolidone, gelatin, hydroxy cellulose, acacia, polyethylene glycol, mannitol, sodium chloride or sodium citrate.
  • these compounds may be encapsulated, tableted or prepared in an emulsion or syrup for oral administration.
  • Pharmaceutically acceptable solid or liquid carriers may be added to enhance or stabilize the composition, or to facilitate preparation of the composition.
  • Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, magnesium stearate or stearic acid, talc, pectin, acacia, agar or gelatin.
  • Liquid carriers include syrup, peanut oil, olive oil, saline and water.
  • the carrier may also include a sustained release material such as glyceryl monostearate or glyceryl distearate, alone or with a wax.
  • the amount of solid carrier varies but, preferably, will be between about 20 mg to about 1 g per dosage unit.
  • the pharmaceutical preparations are made following the conventional techniques of pharmacy involving milling, mixing, granulating, and compressing, when necessary, for tablet forms; or milling, mixing and filling for hard gelatin capsule forms.
  • a liquid carrier When a liquid carrier is used, the preparation will be in the form of a syrup, elixir, emulsion or an aqueous or non-aqueous suspension.
  • Such a liquid formulation may be administered directly p.o. or filled into a soft gelatin capsule.
  • the compounds of this invention may also be combined with excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols and molded into a suppository.
  • excipients such as cocoa butter, glycerin, gelatin or polyethylene glycols and molded into a suppository.
  • the methods of the present invention include topical inhaled and intracolonic administration of the compounds of Formula I.
  • topical administration is meant non-systemic administration, including the application of a compound of the invention externally to the epidermis, to the buccal cavity and instillation of such a compound into the ear, eye and nose, wherein the compound does not significantly enter the blood stream.
  • systemic administration is meant oral, intravenous, intraperitoneal and intramuscular administration.
  • the amount of a compound of the invention (hereinafter referred to as the active ingredient) required for therapeutic or prophylactic effect upon topical administration will, of course, vary with the compound chosen, the nature and severity of the condition being treated and the animal undergoing treatment, and is ultimately at the discretion of the physician While it is possible for an active ingredient to be administered alone as the raw chemical, it is preferable to present it as a pharmaceutical formulation.
  • the active ingredient may comprise, for topical administration, from 0.01 to 5.0 wt%.of the formulation.
  • topical formulations of the present invention both for veterinary and for human medical use, comprise an active ingredient together with one or more acceptable carriers therefor and optionally any other therapeutic ingredients.
  • the carrier must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • Formulations suitable for topical administration include liquid or semi-liquid preparations suitable for penetration through the skin to the site of where treatment is required such as: liniments, lotions, creams, ointments or pastes, and drops suitable for administration to the eye, ear or nose.
  • Drops according to the present invention may comprise sterile aqueous or oily solutions or suspensions and may be prepared by dissolving the active ingredient in a suitable aqueous solution of a bactericidal and/or fungicidal agent and/or any other suitable preservative, and preferably including a surface active agent.
  • the resulting solution may then be clarified by filtration, transferred to a suitable container, which is then sealed and sterilized by autoclaving, or maintaining at 90-100 C for half an hour.
  • the solution may be sterilized by filtration and transferred to the container by an aseptic technique.
  • bactericidal and fungicidal agents suitable for inclusion in the drops are phenylmercuric nitrate or acetate (0.002%), benzalkonium chloride (0.01%) and chlorhexidine acetate (0.01%).
  • Suitable solvents for the preparation of an oily solution include glycerol, diluted alcohol and propylene glycol.
  • Lotions according to the present invention include those suitable for application to the skin or eye.
  • An eye lotion may comprise a sterile aqueous solution optionally containing a bactericide and may be prepared by methods similar to those for the preparation of drops.
  • Lotions or liniments for application to the skin may also include an agent to hasten drying and to cool the skin, such as an alcohol or acetone, and/or a moisturizer such as glycerol or an oil such as castor oil or arachis oil.
  • Creams, ointments or pastes according to the present invention are semi-solid formulations of the active ingredient for external application. They may be made by mixing the active ingredient in finely divided or powdered form, alone or in solution or suspension in an aqueous or non-aqueous fluid, with the aid of suitable machinery, with a greasy or non-greasy basis.
  • the basis may comprise hydrocarbons such as hard, soft or liquid paraffin, glycerol, beeswax, a metallic soap, a mucilage, an oil of natural origin such as almond, corn, arachis, castor or olive oil, wool fat or its derivatives, or a fatty acid such as stearic or oleic acid together with an alcohol such as propylene glycol or macrogols.
  • the formulation may incorporate any suitable surface active agent such as an anionic, cationic or non-ionic surface active agent such as sorbitan esters or polyoxyethylene derivatives thereof.
  • suitable surface active agent such as an anionic, cationic or non-ionic surface active agent such as sorbitan esters or polyoxyethylene derivatives thereof.
  • Suspending agents such as natural gums, cellulose derivatives or in organic materials such as silicaceous silicas, and other ingredients such as lanolin, may also be included.
  • the compounds of Formula I are useful as inhibitors of the IKK-beta kinase phosphorylation of I ⁇ B and as such are inhibitors of NF- ⁇ B activation.
  • the present method utilizes compositions and formulations of said compounds, including pharmaceutical compositions and formulations of said compounds.
  • the present invention particularly provides methods of treatment of diseases associated with inappropriate NF- ⁇ B activation, which methods comprise administering to an animal, particularly a mammal, most particularly a human in need thereof one or more compounds of Formula I.
  • the present invention particularly provides methods for treating inflammatory and tissue repair disorders, particularly rheumatoid arthritis, inflammatory bowel disease, asthma and COPD (chronic obstructive pulmonary disease) osteoarthritis, osteoporosis and fibrotic diseases; dermatosis, including psoriasis, atopic dermatitis and ultraviolet radiation (UN)-induced skin damage, autoimmune diseases including systemic lupus eythematosus, multiple sclerosis, psoriatic arthritis, alkylosing spondylitis, tissue and organ rejection, Alzheimer's disease, stroke, atherosclerosis, restenosis, diabetes, glomerulonephritis, cancer, including Hodgkins disease, cachexia, inflammation associated with infection and certain viral infections, including aquired immune deficiency syndrome (AIDS), adult respiratory distress syndrome and Ataxia Telangiestasia.
  • AIDS aquired immune deficiency syndrome
  • AIDS aquired immune deficiency syndrome
  • parenteral administration of one or more compounds of Formula I is useful.
  • the parenteral dose will be about 0.01 to about 50 mg/kg; preferably between 0.1 and 20 mg/kg, in a manner to maintain the concentration of drug in the plasma at a concentration effective to inhibit IKK-beta and therefore activation of ⁇ F- ⁇ B.
  • the compounds are administered one to four times daily at a level to achieve a total daily dose of about 0.4 to about 80 mg kg/day.
  • the compounds of Formulas I may also be administered orally to the patient, in a manner such that the concentration of drug is sufficient to inhibit IKK-beta and therefore activation of NF- ⁇ B or to achieve any other therapeutic indication as disclosed herein.
  • a pharmaceutical composition containing the compound is administered at an oral dose of between about 0.1 to about 50 mg/kg in a manner consistent with the condition of the patient. Preferably the oral dose would be about 0.5 to about 20 mg/kg.
  • the compounds of Formulas I may also be administered topically to the patient, in a manner such that the concentration of drug is sufficient to inhibit IKK- beta and therefore activation of NF-kB or to achieve any other therapeutic indication as disclosed herein.
  • a pharmaceutical composition containing the compound is administered in a topical formulation of between about 0.01% to about 5% w/w.
  • NF- ⁇ B plays a key role in the regulated expression of a large number of pro- inflammatory mediators including cytokines such as TNF, IL-l ⁇ , IL-6 an IL-8 (Mukaida et al, 1990; Liberman and Baltimore, 1990; Matsusaka et al, 1993), cell adhesion molecules, such as ICAM and VCAM (Marui et al., 1993; Kawai et al, 1995; Ledebur and Parks, 1995), and inducible nitric oxide synthase (iNOS) (Xie et al., 1994; Adcock et al, 1994). (Full reference citations are at the end of this section).
  • cytokines such as TNF, IL-l ⁇ , IL-6 an IL-8
  • cell adhesion molecules such as ICAM and VCAM (Marui et al., 1993; Kawai et al, 1995; Ledebur and Parks, 1995)
  • iNOS
  • mediators are known to play a role in the recruitment of leukocytes at sites of inflammation and in the case of iNOS, may lead to organ destruction in some inflammatory and autoimmune diseases (McCartney-Francis et al., 1993; Kleemann et al, 1993.
  • NF-KB may also play a critical role in the pathogenesis of inflammatory bowel disease (IBD).
  • IBD inflammatory bowel disease
  • Activated NF- ⁇ B is seen in colonic biopsy specimens from Chron's disease and ulcerative colitis patients (Ardite et ah, 1998; Rogler et al., 1998; Schreiber et al., 1998). Activation is evident in the inflamed mucosa but not in uninflamed mucosa (Ardite et al., 1998; Rogler et al., 1998) and is associated with increased IL-8 mRNA expression in the same sites (Ardite et al., 1998).
  • corticosteroid treatment strongly inhibits intestinal NF- ⁇ B activation and reduces colonic inflammation (Ardite et al, 1998; Schreiber et al., 1998). Again, inhibition of IL-8 production through the inhibition of NF- ⁇ B, as has been demonstrated by these compounds would be predicted be beneficial in inflammatory bowel disease.
  • NF- ⁇ B a key regulator of colonic inflammation.
  • Increased NF- B activity is observed in the lamina limbal macrophages in 2,4,6,-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice with p65 being a major component of the activated complexes (Neurath et al., 1996; Neurath and Pettersson, 1997).
  • TNBS 2,4,6,-trinitrobenzene sulfonic acid
  • Local administration of p65 antisense abrogates the signs of established colitis in the treated animals with no signs of toxicity (Neurath et al., 1996; Neurath and Pettersson, 1997).
  • small molecule inhibitors of NF- KB would be useful in the treatment of IBD.
  • NF- ⁇ B is normally present as an inactive cytoplasmic complex
  • recent immunohistochemical studies have indicated that NF- KB is present in the nuclei, and hence active, in the cells comprising human rheumatoid synovium (Handel et al., 1995; Marok et al., 1996; Sioud et al., 1998) and in animal models of the disease (Tsao et al., 1997).
  • the staining is associated with type A synoviocytes and vascular endothelium (Marok et al., 1996).
  • constitutive activation of NF- ⁇ B is seen in cultured synoviocytes
  • NF- ⁇ B may underlie the increased cytokine production and leukocyte infiltration characteristic of inflamed synovium.
  • pro-inflammatory mediators e.g. cytokines and prostanoids
  • the compounds of this invention may be tested in one of several biological assays to determine the concentration of compound, which is required to have a given pharmacological effect.
  • NF- ⁇ B activity may also be measured in an electrophoretic mobility shift assay (EMSA) to assess the presence of NF- ⁇ B protein in the nucleus.
  • ESA electrophoretic mobility shift assay
  • the cells of interest are cultured to a density of 1x10 /mL.
  • the cells are harvested by centrifugation, washed in PBS without Ca 2+ and Mg 2+ and resuspended in PBS with Ca 2+ and Mg 2+ at lxl 0 7 cells/mL.
  • the activation of NF- ⁇ B the cell suspensions are treated with various concentrations of drug or vehicle (DMSO, 0.1%) for 30 min. at 37 °C prior to stimulation with TNF- ⁇ (5.0 ng/mL) for an additional 15 min.
  • DMSO drug or vehicle
  • Cellular and nuclear extracts are prepared follows. Briefly, at the end of the incubation period the cells (lxlO 7 cells) are washed 2x in PBS without Ca 2+ and Mg 2+ . The resulting cell pellets are resuspended in 20 uL of Buffer A (10 mM Hepes (pH 7.9), 10 mM KC1, 1.5 mM MgCl 2 , 0.5 mM dithiothreitol (DTT) and 0.1% NP-40) and incubated on ice for 10 min. The nuclei are pelleted by microcentrifugation at 3500 rpm for 10 min at 4 °C.
  • Buffer A 10 mM Hepes (pH 7.9), 10 mM KC1, 1.5 mM MgCl 2 , 0.5 mM dithiothreitol (DTT) and 0.1% NP-40
  • the resulting supernatant was collected as the cellular extract and the nuclear pellet was resuspended in 15 uL Buffer C (20 mM Hepes (pH 7.9), 0.42 M NaCl, 1.5mM MgCl 2 , 25% glycerol, 0.2 mM EDTA, 0.5 mM DTT, and 0.5 mM phenylmethylsulphonyl fluoride (PMSF)).
  • the suspensions are mixed gently for 20 min at 4 °C then microcentrifuged at 14,000 rpm for 10 min at 4 °C.
  • the supernatant is collected and diluted to 60 uL with Buffer D (20mM Hepes (pH 7.9), 50 mM KC1, 20% glycerol, 0.2 mM EDTA, 0.5 mM DTT, and 0.5 mM PMSF). All samples are stored at -80 °C until analyzed. The protein concentration of the extracts is determined according to the method of Bradford (Bradford, 1976) with BioRad reagents.
  • EMS A electrophoretic mobility shift assay
  • the binding mixture (25 uL) contains 10 mM Hepes-NaOH (pH 7.9), 4 mM Tris-HCl (pH 7.9), 60 mM KC1, 1 mM EDTA, 1 mM dithiothreitol, 10% glycerol, 0.3 mg/mL bovine serum albumin, and 1 ug poly(dI-dC)»poly(dI-dC).
  • the binding mixtures (10 ug nuclear extract protein) are incubated for 20 min at room temperature with 0.5 ng of 32 P-labelled oligonucleotide (50.000-100.000 cpm) in the presence or absence of unlabeled competitor after which the mixture is loaded on a 4% polyacrylamide gel prepared in IX Tris borate/EDTA and electrophoresed at 200 N for 2 h. Following electrophoresis the gels are dried and exposed to film for detection of the binding reaction.
  • Kinase activity was assayed using 50 ng of purified protein in assay buffer (20 mM Hepes, pH 7.7, 2 mM MgCl 2 , 1 mM MnCl 2 , 10 mM ⁇ -glycerophosphate, 10 mM NaF, 10 mM PNPP, 0.3 mM Na3NO4, 1 mM benzamidine, 2 ⁇ M PMSF, 10 ⁇ g/ml aprotinin, 1 ug/mL leupeptin, 1 ug/mL pepstatin, lmM DTT) containing various concentrations of compound or DMSO vehicle and ATP as indicated (Pharmacia Biotech Inc., Piscataway, NJ).
  • the reaction was started by the addition of 200 ng I ⁇ B-GST (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), in a total volume of 50 uL. The reaction was allowed to proceed for 1 h. at 30 °C after which the reaction was terminated by the addition of EDTA to a final concentration of 20 mM.
  • Kinase activity was determined by dissociation-enhanced lanthanide fluorescence immunoassay (Wallac Oy, Turku, Finland) using a phospho-I ⁇ B- ⁇ (Ser32) antibody (New England Biolabs, Inc., Beverly, MA) and an Eu 3+ -labelled anti-rabbit IgG (Wallac Oy, Turku, Finland).
  • the plates were read in a VICTOR 1420 Multilabel Counter (Wallac), using a standard europium protocol (excitation 340 nm, emission 615 nm; fluorescence measured for 400 ⁇ s after a 400 usec delay). Data are expressed as fluorescence (cps) units.
  • IKK- ⁇ was expressed as a GST-tagged protein, and its activity was assessed in a 96-well scintillation proximity assay (SPA). Briefly, IKK- ⁇ was diluted in assay buffer as described above (20 nM final), with various concentrations of compound or DMSO vehicle, 240 nM ATP and 200 nCi [ ⁇ - 33 P]-ATP (10 mCi/mL, 2000 Ci/mmol; NEN Life Science Products, Boston, MA). The reaction was started with the addition of a biotinylated peptide comprising amino acids 15 - 46 of I ⁇ B- ⁇ (American Peptide) to a final concentration of 2.4 ⁇ M, in a total volume of 50 uL.
  • SPA 96-well scintillation proximity assay
  • IKK- ⁇ inhibitors The effect of IKK- ⁇ inhibitors on primary synovial fibroblast mediator production was assesses as follows: Primary cultures of human RSF were obtained by enzymatic digestion of synovium obtained from adult patients with rheumatoid arthritis as previously described (Roshak et al., 1996b). Cells were cultured in Earl's Minimal Essential Medium (EMEM) which contained 10% fetal bovine serum (FBS), 100 units/ml penicillin and 100 ⁇ g/ml streptomycin (GIBCO, Grand Island, ⁇ Y), at 37°C and 5% CO 2 . Cultures were used at passages 4 through 9 in order to obtain a more uniform type B fibroblast population.
  • EMEM Earl's Minimal Essential Medium
  • fibroblasts were plated at 5 x 10 ⁇ cells/mL in 16 mm (diameter) 24 well plates (Costar, Cambridge, MA). Cells (70-80% confluence) were exposed to IL-l ⁇ (1 ng/mL) (Genzyme, Cambridge, MA) for the designated time. Drugs in DMSO vehicle (1%) were added to the cell cultures 15 minutes prior to the addition of IL-1. Studies were conducted 3-4 times using synovial cells from different donors. RSF cellular extracts were prepared from cells treated as described above. Briefly, human RSF were removed by trypsin/EDTA, washed, and harvested by centrifugation.
  • Cellular extracts were prepared as previously described (Dignam etal., 1983; Osbom, etal., 1989). Briefly, at the end of the incubation period the cells (l lO ⁇ cells) were washed 2x in PBS without Ca ⁇ + and Mg2+. The resulting cell pellets were resuspended in 20 uL of Buffer A (10 mM Hepes (pH 7.9), 10 mM KC1, 1.5 mM MgCl 2 , 0.5 mM.
  • Buffer A (10 mM Hepes (pH 7.9), 10 mM KC1, 1.5 mM MgCl 2 , 0.5 mM.
  • DMSO DMSO.
  • Monocytes were activated by the addition of 200 ng/mL endotoxin (LPS; E. coli serotype 026:B6)(Sigma, St. Louis, MO.) and incubated for 24 hrs.
  • LPS endotoxin
  • Cell-free supernates were analyzed by ⁇ LISA for TNF- ⁇ ( ⁇ IA developed at SB), PG ⁇ 2 (Cayman Chemical, Ann Arbor, MI), and IL-8 and IL-6 Biosource International, Camarillo, CA). Viability of the cells was determined by trypan blue exclusion.
  • the inflammatory response induced by the cutaneous application of phorbol ester (PMA) to the external pinnae of Balb/c mice has proven to be a useful model to examine multifactorial inflammatory cell infiltration and inflammatory alteration of epidermis.
  • the intense inflammatory lesion is dominated by neutrophil infiltration, which can be easily quantified by measurement tissue concentration myeloperoxidase, an azuriphilic granular enzyme present in neutrophils.
  • the overall intensity of the inflammatory response can be measured by determination of ear thickness.
  • IR Continuous wave infrared
  • FTIR Fourier transform infrared
  • FTIR spectra were recorded in transmission mode, and band positions are reported in inverse wavenumbers (cm- ). Mass spectra were taken on either VG 70 FE, PE Syx API III, or VG ZAB HF instruments, using fast atom bombardment (FAB) or electrospray (ES) ionization techniques. Elemental analyses were obtained using a Perkin-Elmer 240C 'elemental analyzer. Melting points were taken on a Thomas- Hoover melting point apparatus and are uncorrected. All temperatures are reported in degrees Celsius.
  • Example 4 Preparation of 2-Amino-5-(4-chloro-phenyl)-thiophene-3-carboxylic acid amide Using the procedure described in Example 1 but replacing 4- fluorophenylacetaldehyde with 4-chlorophenylacetaldehyde gave the above titled compound. M.P. 255-257 °C.
  • Example 7a Using the procedure outlined in Example 2 the compound from Example 7a is treated with acetic anhydride in pyridine to give the above titled compound.
  • Example 7b The compound from Example 7b in HBr/acetic acid is treated with bromine at 0 C. The reaction is continued until all of the starting material is consumed. Then the reaction is quenched with water, neutralized and extracted with ethyl acetate. The organic extracts are washed with sodium thiosulfate solution, dried over magnesium sulfate and evaporated to give the above titled compound.
  • Example 7c A mixture of Example 7c (1 equiv.), 4-fluorophenylboronic acid (1 equiv.), catalytic (Pl ⁇ P ⁇ Pd and 2M Na 2 CO3 (aqueous) in toluene/EtOH (4: 1) is heated at reflux in 24 h. The mixture is cooled, and the layers are separated. The aqueous layer is extracted with ethyl acetate, washed with Na 2 CO3 (aq.), dried over MgSO4 and evaporated. Purification by flash chromatography gives the above titled compound. MS (LC/MS) [M+H]+m/e 279.
  • Example 13 Preparation of 5-Acetylamino-[2,3']bithiophenyl-4-carboxylic acid amide Using the method of Example 7d but substituting 3-thiopheneboronic acid for 4-fluorophenylboronic acid gave the above titled compound after preparative reverse phase HPLC. MS (LC/MS) [M+H] + m/e 267.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)

Abstract

La présente invention concerne de nouveaux composés et de nouveaux procédés permettant de traiter des maladies au moyen d'inhibiteurs aminothiophène de la phosphorylation IKK-ß de IλB.
PCT/US2001/031866 2000-10-12 2001-10-12 INHIBITEURS DU NF-λB WO2002030353A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2002533800A JP2004523476A (ja) 2000-10-12 2001-10-12 ＮＦ−κＢ阻害剤
US10/398,847 US20040024047A1 (en) 2001-10-12 2001-10-12 Nf-kb inhibitors
AU2002211663A AU2002211663A1 (en) 2000-10-12 2001-10-12 Nf-$g(k)b inhibitors
EP01979731A EP1324759A4 (fr) 2000-10-12 2001-10-12 Inhibiteurs du nf-g(k)b
US11/237,232 US20060030596A1 (en) 2000-10-12 2005-09-28 NF-kappaB inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23975900P 2000-10-12 2000-10-12
US60/239,759 2000-10-12

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/237,232 Continuation US20060030596A1 (en) 2000-10-12 2005-09-28 NF-kappaB inhibitors

Publications (2)

Publication Number Publication Date
WO2002030353A2 true WO2002030353A2 (fr) 2002-04-18
WO2002030353A3 WO2002030353A3 (fr) 2002-06-27

Family

ID=22903601

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/031866 WO2002030353A2 (fr) 2000-10-12 2001-10-12 INHIBITEURS DU NF-λB

Country Status (4)

Country Link
EP (1) EP1324759A4 (fr)
JP (1) JP2004523476A (fr)
AU (1) AU2002211663A1 (fr)
WO (1) WO2002030353A2 (fr)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003037886A3 (fr) * 2001-10-30 2003-12-24 Pharmacia Corp Derives de carboxamide heteroaromatique destines au traitement des inflammations
EP1448545A1 (fr) * 2001-10-04 2004-08-25 SmithKline Beecham Corporation Inhibiteurs du facteur de transcription nf-kb
US6846834B2 (en) 2000-10-26 2005-01-25 Amgen Inc. Antiinflammation agents
EP1532133A1 (fr) * 2002-06-06 2005-05-25 Smithkline Beecham Corporation Inhibiteurs de nf-:b
EP1532135A1 (fr) * 2002-06-06 2005-05-25 Smithkline Beecham Corporation Inhibiteurs de nf-kb
EP1569924A2 (fr) * 2002-12-06 2005-09-07 Smithkline Beecham Corporation Inhibiteurs du facteur nf-kb
JP2006515355A (ja) * 2003-01-15 2006-05-25 アストラゼネカ・アクチエボラーグ 酵素ｉｋｋ−２阻害剤としてのチオフェンカルボキサミド
US7098240B2 (en) 2001-07-25 2006-08-29 Astrazeneca Ab Compounds
EP1694323A2 (fr) * 2003-12-19 2006-08-30 Elixir Pharmaceuticals, Inc. Procedes de traitement d'un trouble
US7125896B2 (en) 2001-07-25 2006-10-24 Astrazeneca Ab Thiophene carboxamide compounds as inhibitors of enzyme IKK-2
WO2007005534A2 (fr) 2005-06-30 2007-01-11 Smithkline Beecham Corporation Composes chimiques
US7176314B2 (en) 2001-12-05 2007-02-13 Amgen, Inc. Inflammation modulators
US7199119B2 (en) 2002-10-31 2007-04-03 Amgen Inc. Antiinflammation agents
JP2007517843A (ja) * 2004-01-05 2007-07-05 アストラゼネカ アクチボラグ Ｃｈｋ１阻害剤であるチオフェン誘導体
US7358376B2 (en) * 2000-02-12 2008-04-15 Astrazeneca Ab Substituted Thiophene compounds
US7423061B2 (en) 2003-08-15 2008-09-09 Astrazeneca Ab Substitute thiophenes and uses thereof
WO2008118724A1 (fr) 2007-03-23 2008-10-02 Smithkline Beecham Corporation Indole carboxamides en tant qu'inhibiteurs d'ikk2
US7572826B2 (en) 2003-01-15 2009-08-11 Astrazeneca Ab Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme IKK-2
WO2009132050A2 (fr) 2008-04-21 2009-10-29 Otonomy, Inc. Préparations auriculaires de traitement de maladies et états otiques
US7858796B2 (en) 2004-09-21 2010-12-28 Glaxo Group Limited Chemical compounds
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
WO2012046793A1 (fr) * 2010-10-07 2012-04-12 参天製薬株式会社 Nouvel inhibiteur de jak3 contenant, à titre de principe actif, un dérivé de thiophène portant un groupe uréido et un groupe aminocarbonyle à titre de substituants
EP2520292A1 (fr) 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Utilisation de spirangiens pour le traitement ou la prévention des troubles liés à IL-8 ou IL-6
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
US8367706B2 (en) 2007-06-20 2013-02-05 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
US8501780B2 (en) 2004-06-24 2013-08-06 Glaxosmithkline Llc Indazole carboxamides and their use
US10821185B2 (en) 2016-06-29 2020-11-03 Otonomy Inc. Triglyceride otic formulations and uses thereof
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420695B2 (en) * 2008-07-09 2013-04-16 Merck Sharp & Dohme Corp. Inhibitors of janus kinases

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468012A (en) * 1973-08-09 1977-03-23 Beecham Group Ltd 2-amino-3-carboxy-thiophene derivatives
JPH06143838A (ja) * 1992-11-06 1994-05-24 Sankyo Kagaku Kk 感熱転写記録用色素
JP3236683B2 (ja) * 1992-11-06 2001-12-10 大日本印刷株式会社 熱転写用染料及び熱転写シート
PT853083E (pt) * 1997-01-06 2001-12-28 Pfizer Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
US6414013B1 (en) * 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7358376B2 (en) * 2000-02-12 2008-04-15 Astrazeneca Ab Substituted Thiophene compounds
US6846834B2 (en) 2000-10-26 2005-01-25 Amgen Inc. Antiinflammation agents
US7186841B2 (en) 2000-10-26 2007-03-06 Amgen Inc. Antiinflammation agents
US7125896B2 (en) 2001-07-25 2006-10-24 Astrazeneca Ab Thiophene carboxamide compounds as inhibitors of enzyme IKK-2
US7098240B2 (en) 2001-07-25 2006-08-29 Astrazeneca Ab Compounds
US7956084B2 (en) 2001-07-25 2011-06-07 Astrazeneca Ab Phenyl thiophene carboxamide compounds as inhibitors of the enzyme IKK-2
EP1448545A1 (fr) * 2001-10-04 2004-08-25 SmithKline Beecham Corporation Inhibiteurs du facteur de transcription nf-kb
EP1448545A4 (fr) * 2001-10-04 2005-01-12 Smithkline Beecham Corp Inhibiteurs du facteur de transcription nf-kb
US7166639B2 (en) 2001-10-04 2007-01-23 Smithkline Beecham Corporation NF-κB inhibitors
WO2003037886A3 (fr) * 2001-10-30 2003-12-24 Pharmacia Corp Derives de carboxamide heteroaromatique destines au traitement des inflammations
US7176314B2 (en) 2001-12-05 2007-02-13 Amgen, Inc. Inflammation modulators
EP1532133A1 (fr) * 2002-06-06 2005-05-25 Smithkline Beecham Corporation Inhibiteurs de nf-:b
EP1532133A4 (fr) * 2002-06-06 2006-11-15 Smithkline Beecham Corp Inhibiteurs de nf-:b
US7300952B2 (en) 2002-06-06 2007-11-27 Smithkline Beecham Corporation NF-κb inhibitors
EP1532135A4 (fr) * 2002-06-06 2005-11-09 Smithkline Beecham Corp Inhibiteurs de nf-kb
US7375131B2 (en) 2002-06-06 2008-05-20 Smithklinebeecham Corp. NF-κB inhibitors
EP1532135A1 (fr) * 2002-06-06 2005-05-25 Smithkline Beecham Corporation Inhibiteurs de nf-kb
US7199119B2 (en) 2002-10-31 2007-04-03 Amgen Inc. Antiinflammation agents
US7635695B2 (en) 2002-10-31 2009-12-22 Amgen Inc. Antiinflammation agents
EP1569924A4 (fr) * 2002-12-06 2007-02-21 Smithkline Beecham Corp Inhibiteurs du facteur nf-kb
EP1569924A2 (fr) * 2002-12-06 2005-09-07 Smithkline Beecham Corporation Inhibiteurs du facteur nf-kb
US7572826B2 (en) 2003-01-15 2009-08-11 Astrazeneca Ab Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme IKK-2
US7553868B2 (en) 2003-01-15 2009-06-30 Astrazeneca Ab Thiophene carboxamides as inhibitors of the enzyme IKK-2
JP2006515355A (ja) * 2003-01-15 2006-05-25 アストラゼネカ・アクチエボラーグ 酵素ｉｋｋ−２阻害剤としてのチオフェンカルボキサミド
US7423061B2 (en) 2003-08-15 2008-09-09 Astrazeneca Ab Substitute thiophenes and uses thereof
EP1694323A4 (fr) * 2003-12-19 2009-05-13 Elixir Pharmaceuticals Inc Procedes de traitement d'un trouble
JP2007515429A (ja) * 2003-12-19 2007-06-14 エリクシアー ファーマシューティカルズ， インコーポレイテッド 障害を治療する方法
EP1694323A2 (fr) * 2003-12-19 2006-08-30 Elixir Pharmaceuticals, Inc. Procedes de traitement d'un trouble
JP2007517843A (ja) * 2004-01-05 2007-07-05 アストラゼネカ アクチボラグ Ｃｈｋ１阻害剤であるチオフェン誘導体
US8501780B2 (en) 2004-06-24 2013-08-06 Glaxosmithkline Llc Indazole carboxamides and their use
US7858796B2 (en) 2004-09-21 2010-12-28 Glaxo Group Limited Chemical compounds
US8354406B2 (en) 2005-06-30 2013-01-15 Glaxosmithkline Llc Chemical compounds
WO2007005534A2 (fr) 2005-06-30 2007-01-11 Smithkline Beecham Corporation Composes chimiques
US8372875B2 (en) 2007-03-23 2013-02-12 GlaxoSmithKline, LLC Indole carboxamides as IKK2 inhibitors
US8071584B2 (en) 2007-03-23 2011-12-06 Glaxosmithkline Llc Indole carboxamides as IKK2 inhibitors
WO2008118724A1 (fr) 2007-03-23 2008-10-02 Smithkline Beecham Corporation Indole carboxamides en tant qu'inhibiteurs d'ikk2
US8367706B2 (en) 2007-06-20 2013-02-05 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
US10751281B2 (en) 2008-04-21 2020-08-25 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
WO2009132050A2 (fr) 2008-04-21 2009-10-29 Otonomy, Inc. Préparations auriculaires de traitement de maladies et états otiques
US10272034B2 (en) 2008-04-21 2019-04-30 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US11123286B2 (en) 2008-04-21 2021-09-21 Otonomy, Inc. Auris formulations for treating otic diseases and conditions
US11123285B2 (en) 2008-04-21 2021-09-21 Otonomy, Inc. Auris formulations for treating OTIC diseases and conditions
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
WO2012046793A1 (fr) * 2010-10-07 2012-04-12 参天製薬株式会社 Nouvel inhibiteur de jak3 contenant, à titre de principe actif, un dérivé de thiophène portant un groupe uréido et un groupe aminocarbonyle à titre de substituants
EP2520292A1 (fr) 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Utilisation de spirangiens pour le traitement ou la prévention des troubles liés à IL-8 ou IL-6
US10821185B2 (en) 2016-06-29 2020-11-03 Otonomy Inc. Triglyceride otic formulations and uses thereof

Also Published As

Publication number Publication date
WO2002030353A3 (fr) 2002-06-27
JP2004523476A (ja) 2004-08-05
EP1324759A2 (fr) 2003-07-09
EP1324759A4 (fr) 2004-05-12
AU2002211663A1 (en) 2002-04-22

Similar Documents

Publication Publication Date Title
US7166639B2 (en) NF-κB inhibitors
WO2002030353A2 (fr) INHIBITEURS DU NF-λB
US20060116419A1 (en) Nf-kb inhibitors
US7375131B2 (en) NF-κB inhibitors
US6492425B1 (en) Inhibitors of transcription factor-NF-κB
WO2002030423A1 (fr) Inhibiteurs du nf-$g(k)b
US7300952B2 (en) NF-κb inhibitors
US7183311B2 (en) NF-κB inhibitors
AU4699699A (en) Inhibitors of transcription factor NF-KappaB
US20040024047A1 (en) Nf-kb inhibitors
US20040006118A1 (en) Nf-kb inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10398847

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2001979731

Country of ref document: EP

Ref document number: 2002533800

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2001979731

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2001979731

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载